Suppr超能文献

中国9年期间唑类药物敏感性率持续下降。

Continual Decline in Azole Susceptibility Rates in Over a 9-Year Period in China.

作者信息

Wang Yao, Fan Xin, Wang He, Kudinha Timothy, Mei Ya-Ning, Ni Fang, Pan Yu-Hong, Gao Lan-Mei, Xu Hui, Kong Hai-Shen, Yang Qing, Wang Wei-Ping, Xi Hai-Yan, Luo Yan-Ping, Ye Li-Yan, Xiao Meng

机构信息

Department of Laboratory Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.

Beijing Key Laboratory for Mechanisms Research and Precision Diagnosis of Invasive Fungal Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.

出版信息

Front Microbiol. 2021 Jul 9;12:702839. doi: 10.3389/fmicb.2021.702839. eCollection 2021.

Abstract

BACKGROUND

There have been reports of increasing azole resistance in , especially in the Asia-Pacific region. Here we report on the epidemiology and antifungal susceptibility of causing invasive candidiasis in China, from a 9-year surveillance study.

METHODS

From August 2009 to July 2018, isolates ( = 3702) were collected from 87 hospitals across China. Species identification was carried out by mass spectrometry or rDNA sequencing. Antifungal susceptibility was determined by Clinical and Laboratory Standards Institute disk diffusion (CHIF-NET10-14, = 1510) or Sensititre YeastOne (CHIF-NET15-18, = 2192) methods.

RESULTS

Overall, 22.2% (823/3702) of the isolates were resistant to fluconazole, with 90.4% (744/823) being cross-resistant to voriconazole. In addition, 16.9 (370/2192) and 71.7% (1572/2192) of the isolates were of non-wild-type phenotype to itraconazole and posaconazole, respectively. Over the 9 years of surveillance, the fluconazole resistance rate continued to increase, rising from 5.7 (7/122) to 31.8% (236/741), while that for voriconazole was almost the same, rising from 5.7 (7/122) to 29.1% (216/741), with no significant statistical differences across the geographic regions. However, significant difference in fluconazole resistance rate was noted between isolates cultured from blood (27.2%, 489/1799) and those from non-blood (17.6%, 334/1903) specimens (-value < 0.05), and amongst isolates collected from medical wards (28.1%, 312/1110) versus intensive care units (19.6%, 214/1092) and surgical wards (17.9%, 194/1086) (Bonferroni adjusted -value < 0.05). Although echinocandin resistance remained low (0.8%, 18/2192) during the surveillance period, it was observed in most administrative regions, and one-third (6/18) of these isolates were simultaneously resistant to fluconazole.

CONCLUSION

The continual decrease in the rate of azole susceptibility among strains has become a nationwide challenge in China, and the emergence of multi-drug resistance could pose further threats. These phenomena call for effective efforts in future interventions.

摘要

背景

有报道称念珠菌对唑类药物的耐药性不断增加,尤其是在亚太地区。在此,我们通过一项为期9年的监测研究,报告中国引起侵袭性念珠菌病的念珠菌的流行病学及抗真菌药敏情况。

方法

2009年8月至2018年7月,从中国87家医院收集念珠菌分离株(n = 3702)。通过质谱法或rDNA测序进行菌种鉴定。采用美国临床和实验室标准协会纸片扩散法(CHIF-NET10 - 14,n = 1510)或Sensititre YeastOne法(CHIF-NET15 - 18,n = 2192)测定抗真菌药敏。

结果

总体而言,22.2%(823/3702)的分离株对氟康唑耐药,其中90.4%(744/823)对伏立康唑交叉耐药。此外,分别有16.9%(370/2192)和71.7%(1572/2192)的分离株对伊曲康唑和泊沙康唑呈非野生型表型。在9年的监测期间,氟康唑耐药率持续上升,从5.7%(7/122)升至31.8%(236/741),而伏立康唑的耐药率几乎相同,从5.7%(7/122)升至29.1%(216/741),各地理区域间无显著统计学差异。然而,血液培养分离株的氟康唑耐药率(27.2%,489/1799)与非血液标本分离株(17.6%,334/1903)之间存在显著差异(P值<0.05),且医疗病房收集的分离株(28.1%,312/1110)与重症监护病房(19.6%,214/1092)及外科病房(17.9%,194/1086)的分离株之间也存在显著差异(Bonferroni校正P值<0.05)。尽管在监测期间棘白菌素耐药率仍较低(0.8%,18/2192),但在大多数行政区均有发现,其中三分之一(6/18)的分离株同时对氟康唑耐药。

结论

念珠菌菌株对唑类药物的药敏率持续下降已成为中国全国性的挑战,多重耐药的出现可能构成进一步威胁。这些现象需要在未来的干预措施中做出有效努力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a1c7/8299486/8022ae3d5b92/fmicb-12-702839-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验